Vici Health Sciences Expands Staff and Footprint in Maryland to Meet Customer Demands

Share Article

Expansion will allows Vici Health Sciences to meet the growing demand from pharmaceutical companies for its services, especially with the expansion of capabilities in both oral and parenteral dosage forms.

A FULL SERVICE PHARMACEUTICAL R&D COMPANY
We work hard to provide our clients innovative R&D solutions to bring their drugs to the market. Our clients want to develop high quality pharmaceutical drug products rapidly and clearly recognize the value we are able to provide.

Vici Health Sciences announces it is breaking ground in expanding its pharmaceutical product development lab in Maryland. Emphasis will be in expanding capabilities in both oral and parenteral dosage forms. With the increased size and expanded capabilities, Vici Health Sciences will be well positioned to meet the growing demand for its pharmaceutical formulation and analytical method development services. Founded in 2016 with the aim of rapidly developing drugs to meet acute and long-term market needs, Vici currently works with over 10 different pharmaceutical companies and continues to expand its client base. The current expansion is focused on improving capabilities in manufacturing GMP clinical supplies and increases Vici’s ability to handle additional clients simultaneously.

Dr Anish Dhanarajan, CEO and co-founder stated: “We work hard to provide our clients innovative R&D solutions to bring their drugs to the market. Our clients want to develop high quality pharmaceutical drug products rapidly and clearly recognize the value we are able to provide. This expansion will allow us to meet the growing demand for our services.”

About Vici Health Sciences LLC
Vici Health Sciences (Vici) is a U.S. based pharmaceutical research and development company. Vici is focused on providing innovative, flexible, high quality, and low-cost R&D services to small and mid-sized pharmaceutical companies that need to grow their product portfolio. Vici currently focuses on oral and injectable dosage forms and operates an R&D and GMP facility capable of developing formulations, analytical methods, and manufacturing phase 1/pilot clinical supplies.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Anish Dhanarajan
Visit website